From GlobeNewswire: 2025-06-06 03:45:00

Vivoryon Therapeutics N.V. presented meta-analysis data of VIVIAD and VIVA-MIND studies at ERA 2025, showing significant improvement in kidney function with varoglutamstat. The Phase 2 studies demonstrated a consistent improvement in eGFR in elderly patients, with a larger effect size in participants with diabetes. The next step is a Phase 2b trial in patients with diabetic kidney disease to further investigate efficacy. Varoglutamstat is a first-in-class glutaminyl cyclase inhibitor with anti-inflammatory and anti-fibrotic effects. The presentation was well-received at the ERA Congress, showcasing the potential of this innovative treatment for kidney diseases.



Read more at GlobeNewswire: Vivoryon Therapeutics N.V. Presents Meta-analysis Data of